Khurana, Sandhya; Brusselle, Guy G.; Bel, Elisabeth H. et al.
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX StudyCLINICAL THERAPEUTICS. Bd. 41. H. 10. 2019 S. 2041-2056
Schmidt-Hieber, Martin; Teschner, Daniel; Maschmeyer, Georg et al.
Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuationEXPERT REVIEW OF ANTI-INFECTIVE THERAPY. Bd. 17. H. 12. 2019 S. 983-995
Ruecker, Frank G.; Agrawal, Mridul; Corbacioglu, Andrea et al.
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupBLOOD. Bd. 134. H. 19. 2019 S. 1608-1618
Schlenk, Richard F.; Weber, Daniela; Fiedler, Walter et al.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITDBLOOD. Bd. 133. H. 8. 2019 S. 840-851
Sasca, Daniel; Szybinski, Jakub; Schueler, Andrea et al.
NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AMLBLOOD. Bd. 133. H. 21. 2019 S. 2305-2319
Bousquet, J. Jean; Schunemann, Holger J.; Togias, Alkis et al.
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseasesCLINICAL AND TRANSLATIONAL ALLERGY. Bd. 9. H. 1. 2019
Singh, Vijay Kumar; Werner, Sebastian; Schwalm, Simone et al.
NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphomaONCOIMMUNOLOGY. 2019
Katsaounou, Paraskevi; Buhl, Roland; Brusselle, Guy et al.
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthmaRESPIRATORY MEDICINE. Bd. 150. 2019 S. 51-62
Dimopoulos, Meletios A.; Gay, Francesca; Schjesvold, Fredrik et al.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialLANCET. Bd. 393. H. 10168. 2019 S. 253-264
Papachristofilou, Alexandros; Hipp, Madeleine M.; Klinkhardt, Ute et al.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancerJOURNAL FOR IMMUNOTHERAPY OF CANCER. Bd. 7. 2019